文献速递妇科

在ARIEL3这项III期随机安慰剂对照试验中,复发性卵巢癌患者接受芦卡帕利维持治疗的患者报告结局

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
PubMed 文献 · Gynecol Oncol · 2023-05-30

ARIEL3试验比较复发性卵巢癌患者接受芦卡帕利(600 mg每日两次)或安慰剂维持治疗的NFOSI-18疾病相关症状-躯体(DRS-P)和总分变化。意向治疗人群中,芦卡帕利组较安慰剂组恶化风险更高(4分恶化定义HR 1.85,95%CI 1.46-2.36),DRS-P首次恶化中位时间1.9个月 vs 7.0个月。作者认为PARP抑制剂的不良反应影响应与临床获益权衡。

要点

  • 芦卡帕利维持治疗较安慰剂增加患者报告症状恶化风险,4分恶化定义HR 1.85(95%CI 1.46-2.36)。
  • DRS-P首次恶化中位时间芦卡帕利组1.9个月 vs 安慰剂组7.0个月。
  • 约20%患者在治疗周期中报告中度至高度副作用困扰。

核心结论

  • 在维持治疗背景下,芦卡帕利较安慰剂与更高的患者报告症状恶化风险相关,PARP抑制剂的不良反应影响应与临床获益权衡。

研究设计与样本

  • ARIEL3(NCT01968213)为III期随机安慰剂对照试验,纳入对二线或以上铂类化疗有反应的卵巢癌患者,比较芦卡帕利600 mg每日两次与安慰剂维持治疗。
  • NFOSI-18 DRS-P和总分量表为次要终点,采用混合模型重复测量分析较基线的变化,Cox回归分析首次和确认恶化时间。

主要发现

  • 意向治疗人群中,芦卡帕利组较安慰剂组恶化风险更高(4分恶化定义HR 1.85,95%CI 1.46-2.36)。
  • DRS-P首次恶化中位时间芦卡帕利组1.9个月 vs 安慰剂组7.0个月。
  • 确认恶化结果与首次恶化结果相似。
  • GP5报告中度/高度副作用困扰的患者比例在各治疗周期中波动于约20%。
  • BRCA突变和同源重组缺陷队列结果与意向治疗人群总体相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare NFOSI-18 Disease Related Symptoms - Physical (DRSP), Total score, and side effect bother between maintenance rucaparib (600 mg twice daily) vs. placebo in the phase III ARIEL3 trial. METHODS: ARIEL3 (NCT01968213) included patients with ovarian carcinoma who responded to second-line or later platinum-based chemotherapy. The NFOSI-18 DRS-P and Total scales were secondary endpoints. The NFOSI-18 contains a side effect impact item (GP5): "I am bothered by side effects of treatment." We compared treatment arms on change from baseline of DRS-P and Total scores using mixed models with repeated measures (MRMM). Time to first and confirmed deterioration of NFOSI-18 DRS-P and Total scales were analyzed using Cox regression. We also calculated the proportion of patients reporting moderate to high side effect bother on GP5. RESULTS: In the intention-to-treat (ITT) cohort, mean change from baseline favored the placebo. Compared to placebo, rucaparib was associated with higher risk of deterioration [e.g., 4-point deteriorator definition hazard ratio (HR): 1.85; 95% CI: 1.46, 2.36; median time to first deterioration on DRSP: 1.9 vs. 7.0 months]. Confirmed deterioration results resembled those for first deterioration. Proportions of patients reporting moderate/high side effect bother on GP5 fluctuated around 20% across treatment cycles. Results in BRCA mutant and homologous recombination deficient cohorts were generally similar to those from the ITT cohort. CONCLUSION: This placebo-controlled study in the maintenance therapy setting provides a unique view of the impact of PARP inhibition on the patient-reported outcomes that are commonly used in ovarian cancer clinical trials. Information regarding the adverse side effect impact of PARP inhibitors should be weighed against their clinical benefit.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Peipert JD, Goble S, Isaacson J, et al. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial. Gynecol Oncol. 2023. PMID: 37262961. doi:10.1016/j.ygyno.2023.05.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。